AbbVie Inc. is 310.3x more valuable than MoonLake Immunotherapeutics by market capitalization ($399.47 B vs $1.29 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MLTX | ABBV |
|---|---|---|
| Market cap | $1.29 B | $399.47 B |
| US-listed rank | #2445 | #28 |
| Revenue (latest FY) | - | $61.16B |
| Net income (latest FY) | -$227.32M | $4.23B |
| Net margin | - | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 296 | 1,008 |
AbbVie Inc. is 310.3x more valuable than MoonLake Immunotherapeutics by market capitalization ($399.47 B vs $1.29 B).
Full pages: MoonLake Immunotherapeutics and AbbVie Inc., or browse the full rankings.